By David Bautz, PhDNASDAQ:OPNTREAD THE FULL OPNT RESEARCH REPORTBusiness UpdateOPNT003 UpdateEarlier in 2018, Opiant (NASDAQ:OPNT) announced the receipt of a $7.4 million grant from the National Institute on Drug Abuse (NIDA) to fund the development of OPNT003, a long-lasting opioid antagonist for the treatment of opioid overdose. OPNT003 is...
By Brian Marckx, CFAOTC:SMLRREAD THE FULL SMLR RESEARCH REPORTQ2 2018 Results: Huge Beat to Our #s. Huge Upward Revisions to Our Model and Price Target…Semler’s (OTC:SMLR) results in each of the last few quarters have indicated that the company could be one of those needle-in-a-haystack type of investments. Q2...
By Lisa ThompsonNASDAQ:RVLTREAD THE FULL RVLT RESEARCH REPORTRevolution Lighting Technologies (NASDAQ:RVLT) missed its revenue guidance by reporting Q2 revenues of $36.4 million versus $43.4 million a year ago, down 16%. A few large opportunities that were won, were expected to have started shipping in Q2, but slipped out of...
By John Vandermosten, CFANASDAQ:RXIIOn August 1st RXi Pharmaceuticals (NASDAQ:RXII) issued a press release announcing positive results from their RXI-109-1501 Phase I/II trial for retinal scarring. The primary outcome for the trial was to determine the safety of RXI-109 and to measure the pharmacokinetic profile of the drug in blood....
OTC:CVSISan Diego, California-based CV Sciences, Inc. (OTC:CVSI) manufactures hemp-based phytocannabinoids including cannabidiol (CBD) oil and also develops specialty pharmaceutical therapeutics. The company reported 2Q18 results yesterday that reflect the benefits of its strategy. According to Forbes, “CBD, short for cannabidiol, is a compound found in cannabis that has gained...
By Brian Marckx, CFANASDAQ:VIVEREAD THE FULL VIVE RESEARCH REPORTOn July 30th FDA issued a Safety Communications letter warning against the use of “Energy-Based Devices to Perform Vaginal ‘Rejuvenation’ of Vaginal Cosmetic Procedures”. The purpose of the letter is to “alert patients and health care providers that the use of...
By Lisa ThompsonNASDAQ:OIIMREAD THE FULL OIIM RESEARCH REPORTO2Micro (NASDAQ:OIIM) reported Q2 2018 revenues of $15.2 million, up 8% sequentially, and 5% year over year and within the range of guidance of up 2-10%. The company returned to growth after two down quarters. Guidance for revenue for the third quarter...
OTC:ZENONASDAQ:CTXRCitius Pharmaceuticals, Inc. (NASDAQ:CTXR) is a specialty pharmaceutical company focused on the development and commercialization of proprietary formulations of already-approved drugs which target large and growing markets.   By reformulating, patenting and expanding the indicated uses of drugs that have previously been approved by the FDA, Citius avoids much of...
By Brian Marckx, CFANASDAQ:EYEGREAD THE FULL EYEG RESEARCH REPORTFDA Approves IDEs for Both OBG Clinical Studies; i.e. the second PRK pilot study and initial PE pilot studyAs we noted in our Q1 ’18 earnings update in late-May, Eyegate Pharmaceuticals' (NASDAQ:EYEG) diligence in rapidly responding to FDAs follow-on questions related...
By Steven Ralston, CFAOTC:ALPEREAD THE FULL ALPE RESEARCH REPORTalpha-En Corp (OTC:ALPE) is a technology development company, primarily focusing on the development of a commercially viable process for the production of high-purity lithium metal and of a thin film lithium anode for use in the next generation of lithium high-energy...